Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research

M. R. Bishop; B. R. Logan; S. Gandham; B. J. Bolwell; J. Y. Cahn; H. M. Lazarus; M. R. Litzow; D. I. Marks; P. H. Wiernik; P. L. McCarthy; J. A. Russell; C. B. Miller; J. Sierra; G. Milone; A. Keating; F. R. Loberiza; S. Giralt; M. M. Horowitz; D. J. Weisdorf

doi:10.1038/sj.bmt.1705952

Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research

M. R. Bishop, B. R. Logan, S. Gandham, B. J. Bolwell, J. Y. Cahn, H. M. Lazarus, M. R. Litzow, D. I. Marks, P. H. Wiernik, P. L. McCarthy, J. A. Russell, C. B. Miller, J. Sierra, G. Milone, A. Keating, F. R. Loberiza, S. Giralt, M. M. Horowitz, D. J. Weisdorf

Hematology

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two transplant registries to determine outcomes between Auto and URD HSCT for 260 adult ALL patients in first (CR1) or second (CR2) CR. All patients received a myeloablative conditioning regimen. The median follow-up was 77 (range 12-170) months. TRM at 1 year post transplant was significantly higher with URD HSCT; however, there were minimal differences in TRM according to disease status. Relapse was higher with Auto HSCT and was increased in patients transplanted in CR2. Five-year leukemia-free (37 vs 39%) and overall survival (OS) rates (38 vs 39%) were similar for Auto HSCT vs URD HSCT in CR1. There were trends favoring URD HSCT in CR2. The long-term follow-up in this analysis demonstrated that either Auto or URD HSCT could result in long-term leukaemia-free survival and OS for adult ALL patients. The optimal time (CR1 vs CR2) and technique to perform HSCT remains an important clinical question for adult ALL patients.

Original language	English (US)
Pages (from-to)	635-642
Number of pages	8
Journal	Bone Marrow Transplantation
Volume	41
Issue number	7
DOIs	https://doi.org/10.1038/sj.bmt.1705952
State	Published - Apr 2008

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1705952

Fingerprint Dive into the research topics of 'Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research'. Together they form a unique fingerprint.

Cite this

Bishop, M. R., Logan, B. R., Gandham, S., Bolwell, B. J., Cahn, J. Y., Lazarus, H. M., Litzow, M. R., Marks, D. I., Wiernik, P. H., McCarthy, P. L., Russell, J. A., Miller, C. B., Sierra, J., Milone, G., Keating, A., Loberiza, F. R., Giralt, S., Horowitz, M. M., & Weisdorf, D. J. (2008). Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplantation, 41(7), 635-642. https://doi.org/10.1038/sj.bmt.1705952

Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation : A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. / Bishop, M. R.; Logan, B. R.; Gandham, S.; Bolwell, B. J.; Cahn, J. Y.; Lazarus, H. M.; Litzow, M. R.; Marks, D. I.; Wiernik, P. H.; McCarthy, P. L.; Russell, J. A.; Miller, C. B.; Sierra, J.; Milone, G.; Keating, A.; Loberiza, F. R.; Giralt, S.; Horowitz, M. M.; Weisdorf, D. J.

In: Bone Marrow Transplantation, Vol. 41, No. 7, 04.2008, p. 635-642.

Research output: Contribution to journal › Article › peer-review

Bishop, MR, Logan, BR, Gandham, S, Bolwell, BJ, Cahn, JY, Lazarus, HM, Litzow, MR, Marks, DI, Wiernik, PH, McCarthy, PL, Russell, JA, Miller, CB, Sierra, J, Milone, G, Keating, A, Loberiza, FR, Giralt, S, Horowitz, MM & Weisdorf, DJ 2008, 'Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research', Bone Marrow Transplantation, vol. 41, no. 7, pp. 635-642. https://doi.org/10.1038/sj.bmt.1705952

Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM et al. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplantation. 2008 Apr;41(7):635-642. https://doi.org/10.1038/sj.bmt.1705952

Bishop, M. R. ; Logan, B. R. ; Gandham, S. ; Bolwell, B. J. ; Cahn, J. Y. ; Lazarus, H. M. ; Litzow, M. R. ; Marks, D. I. ; Wiernik, P. H. ; McCarthy, P. L. ; Russell, J. A. ; Miller, C. B. ; Sierra, J. ; Milone, G. ; Keating, A. ; Loberiza, F. R. ; Giralt, S. ; Horowitz, M. M. ; Weisdorf, D. J. / Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation : A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. In: Bone Marrow Transplantation. 2008 ; Vol. 41, No. 7. pp. 635-642.

@article{92b3c6d5a3d34f34981f0ff33301eee0,

title = "Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research",

abstract = "For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two transplant registries to determine outcomes between Auto and URD HSCT for 260 adult ALL patients in first (CR1) or second (CR2) CR. All patients received a myeloablative conditioning regimen. The median follow-up was 77 (range 12-170) months. TRM at 1 year post transplant was significantly higher with URD HSCT; however, there were minimal differences in TRM according to disease status. Relapse was higher with Auto HSCT and was increased in patients transplanted in CR2. Five-year leukemia-free (37 vs 39%) and overall survival (OS) rates (38 vs 39%) were similar for Auto HSCT vs URD HSCT in CR1. There were trends favoring URD HSCT in CR2. The long-term follow-up in this analysis demonstrated that either Auto or URD HSCT could result in long-term leukaemia-free survival and OS for adult ALL patients. The optimal time (CR1 vs CR2) and technique to perform HSCT remains an important clinical question for adult ALL patients.",

author = "Bishop, {M. R.} and Logan, {B. R.} and S. Gandham and Bolwell, {B. J.} and Cahn, {J. Y.} and Lazarus, {H. M.} and Litzow, {M. R.} and Marks, {D. I.} and Wiernik, {P. H.} and McCarthy, {P. L.} and Russell, {J. A.} and Miller, {C. B.} and J. Sierra and G. Milone and A. Keating and Loberiza, {F. R.} and S. Giralt and Horowitz, {M. M.} and Weisdorf, {D. J.}",

note = "Funding Information: The CIBMTR is supported by Public Health Service Grant U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute; Office of Naval Research; Health Services Research Administration (DHHS); and grants from AABB; Abbott Laboratories; Aetna; AIG Medical Excess; American Red Cross; Amgen Inc.; Anonymous donation to the Medical College of Wisconsin; AnorMED Inc.; Astellas Pharma US Inc.; Berlex Laboratories Inc.; Biogen IDEC Inc.; Blue Cross and Blue Shield Association; BRT Laboratories Inc.; Celgene Corp.; Cell Therapeutics Inc.; CelMed Biosciences; Cubist Pharmaceuticals; Dynal Biotech, LLC; Edwards Lifesciences RMI; Endo Pharmaceuticals Inc.; Enzon Pharmaceuticals Inc.; ESP Pharma; Gambro BCT Inc.; Genzyme Corporation; GlaxoSmithKline Inc.; Histogenetics Inc.; Human Genome Sciences; International Waldenstrom Macroglobulinemia Foundation; Kirin Brewery Company; Ligand Pharmaceuticals Inc.; Merck & Company; Millennium Pharmaceuticals; Miller Pharmacal Group; Milliman USA Inc.; Miltenyi Biotec; National Center for Biotechnology Inform ation; National Leukemia Research Association; National Marrow Donor Program; Nektar Therapeutics; NeoRx Corporation; Novartis Pharmaceuticals Inc.; Novo Nordisk Pharmaceuticals; Ortho Biotech Inc.; Osiris Therapeutics Inc.; Pall Medical; Pfizer Inc.; Pharmion Corp.; Protein Design Labs Inc.; QOL Medical; Roche Laboratories; StemCyte Inc.; Stemco Biomedical; StemSoft Software Inc.; SuperGen Inc.; Sysmex; The Marrow Foundation; THERAKOS, a Johnson & Johnson Co.; University of Colorado Cord Blood Bank; Valeant Pharmaceuticals; ViaCell Inc.; ViraCor Laboratories; WB Saunders Mosby Churchill; Wellpoint Inc.; and Zelos Therapeutics Inc. The views expressed in this article do not reflect the official policy or position of the National Cancer Institute, the Depart ment of the Navy, the Department of Defense, or the Government of the United States. Funding Information: This research has been supported by funding from the National Marrow Donor Program, the Health Resources and Services administration No. 240-97-0036 and the Office of Naval Research N00014-96-2-0016 and N00014-99-2-0006 to the National Marrow Donor Program.",

year = "2008",

month = apr,

doi = "10.1038/sj.bmt.1705952",

language = "English (US)",

volume = "41",

pages = "635--642",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation

T2 - A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research

AU - Bishop, M. R.

AU - Logan, B. R.

AU - Gandham, S.

AU - Bolwell, B. J.

AU - Cahn, J. Y.

AU - Lazarus, H. M.

AU - Litzow, M. R.

AU - Marks, D. I.

AU - Wiernik, P. H.

AU - McCarthy, P. L.

AU - Russell, J. A.

AU - Miller, C. B.

AU - Sierra, J.

AU - Milone, G.

AU - Keating, A.

AU - Loberiza, F. R.

AU - Giralt, S.

AU - Horowitz, M. M.

AU - Weisdorf, D. J.

N1 - Funding Information: The CIBMTR is supported by Public Health Service Grant U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute; Office of Naval Research; Health Services Research Administration (DHHS); and grants from AABB; Abbott Laboratories; Aetna; AIG Medical Excess; American Red Cross; Amgen Inc.; Anonymous donation to the Medical College of Wisconsin; AnorMED Inc.; Astellas Pharma US Inc.; Berlex Laboratories Inc.; Biogen IDEC Inc.; Blue Cross and Blue Shield Association; BRT Laboratories Inc.; Celgene Corp.; Cell Therapeutics Inc.; CelMed Biosciences; Cubist Pharmaceuticals; Dynal Biotech, LLC; Edwards Lifesciences RMI; Endo Pharmaceuticals Inc.; Enzon Pharmaceuticals Inc.; ESP Pharma; Gambro BCT Inc.; Genzyme Corporation; GlaxoSmithKline Inc.; Histogenetics Inc.; Human Genome Sciences; International Waldenstrom Macroglobulinemia Foundation; Kirin Brewery Company; Ligand Pharmaceuticals Inc.; Merck & Company; Millennium Pharmaceuticals; Miller Pharmacal Group; Milliman USA Inc.; Miltenyi Biotec; National Center for Biotechnology Inform ation; National Leukemia Research Association; National Marrow Donor Program; Nektar Therapeutics; NeoRx Corporation; Novartis Pharmaceuticals Inc.; Novo Nordisk Pharmaceuticals; Ortho Biotech Inc.; Osiris Therapeutics Inc.; Pall Medical; Pfizer Inc.; Pharmion Corp.; Protein Design Labs Inc.; QOL Medical; Roche Laboratories; StemCyte Inc.; Stemco Biomedical; StemSoft Software Inc.; SuperGen Inc.; Sysmex; The Marrow Foundation; THERAKOS, a Johnson & Johnson Co.; University of Colorado Cord Blood Bank; Valeant Pharmaceuticals; ViaCell Inc.; ViraCor Laboratories; WB Saunders Mosby Churchill; Wellpoint Inc.; and Zelos Therapeutics Inc. The views expressed in this article do not reflect the official policy or position of the National Cancer Institute, the Depart ment of the Navy, the Department of Defense, or the Government of the United States. Funding Information: This research has been supported by funding from the National Marrow Donor Program, the Health Resources and Services administration No. 240-97-0036 and the Office of Naval Research N00014-96-2-0016 and N00014-99-2-0006 to the National Marrow Donor Program.

PY - 2008/4

Y1 - 2008/4

N2 - For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two transplant registries to determine outcomes between Auto and URD HSCT for 260 adult ALL patients in first (CR1) or second (CR2) CR. All patients received a myeloablative conditioning regimen. The median follow-up was 77 (range 12-170) months. TRM at 1 year post transplant was significantly higher with URD HSCT; however, there were minimal differences in TRM according to disease status. Relapse was higher with Auto HSCT and was increased in patients transplanted in CR2. Five-year leukemia-free (37 vs 39%) and overall survival (OS) rates (38 vs 39%) were similar for Auto HSCT vs URD HSCT in CR1. There were trends favoring URD HSCT in CR2. The long-term follow-up in this analysis demonstrated that either Auto or URD HSCT could result in long-term leukaemia-free survival and OS for adult ALL patients. The optimal time (CR1 vs CR2) and technique to perform HSCT remains an important clinical question for adult ALL patients.

AB - For adults with high-risk or recurrent ALL who lack a suitable sibling donor, the decision between autologous (Auto) and unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is difficult due to variable risks of relapse and treatment-related mortality (TRM). We analysed data from two transplant registries to determine outcomes between Auto and URD HSCT for 260 adult ALL patients in first (CR1) or second (CR2) CR. All patients received a myeloablative conditioning regimen. The median follow-up was 77 (range 12-170) months. TRM at 1 year post transplant was significantly higher with URD HSCT; however, there were minimal differences in TRM according to disease status. Relapse was higher with Auto HSCT and was increased in patients transplanted in CR2. Five-year leukemia-free (37 vs 39%) and overall survival (OS) rates (38 vs 39%) were similar for Auto HSCT vs URD HSCT in CR1. There were trends favoring URD HSCT in CR2. The long-term follow-up in this analysis demonstrated that either Auto or URD HSCT could result in long-term leukaemia-free survival and OS for adult ALL patients. The optimal time (CR1 vs CR2) and technique to perform HSCT remains an important clinical question for adult ALL patients.

UR - http://www.scopus.com/inward/record.url?scp=42149177725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149177725&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705952

DO - 10.1038/sj.bmt.1705952

M3 - Article

C2 - 18084335

AN - SCOPUS:42149177725

VL - 41

SP - 635

EP - 642

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -